Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia | Zendy

Yosuke Suzuki | Zendy; Kanako Kawasaki | Zendy; Yuhki Sato | Zendy; Issei Tokimatsu | Zendy; Hiroki Itoh | Zendy; Kazufumi Hiramatsu | Zendy; Masaharu Takeyama | Zendy; Junichi Kadota | Zendy

Open Access

Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant <b><i>Staphylococcus aureus </i></b>Pneumonia

Author(s) -

Yosuke Suzuki,

Kanako Kawasaki,

Yuhki Sato,

Issei Tokimatsu,

Hiroki Itoh,

Kazufumi Hiramatsu,

Masaharu Takeyama,

Junichi Kadota

Publication year - 2012

Publication title -

chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 54

eISSN - 1421-9794

pISSN - 0009-3157

DOI - 10.1159/000343162

Subject(s) - pharmacokinetics , nephrotoxicity , vancomycin , pharmacodynamics , medicine , area under the curve , staphylococcus aureus , antibiotics , pharmacology , chemistry , toxicity , biology , biochemistry , bacteria , genetics

We analyzed the pharmacokinetic-pharmacodynamic relationship of vancomycin to determine the drug exposure parameters that correlate with the efficacy and nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus pneumonia and evaluated the need to use peak concentration in therapeutic drug monitoring (TDM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research